The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3)

Palie, O.; Michel, Pierre; Ménard, Jean-François; Rousseau, Caroline; Rio, E.; Bridji, B.; Benyoucef, Ahmed; Meyer, Marc-Étienne; Jalali, K; Bardet, Stéphane; M'vondo, Che Mabubu; Olivier, Pierre; Faure, Guillaume; Itti, Emmanuel; Diana, C.; Houzard, C.; Mornex, F.; Fiore, Frédéric Di; Véra, Pierre

doi:10.1007/s00259-013-2450-7

Cited by 43 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is an important result for the robustness and future development of these tracers in nuclear medicine. Similar results were previously shown by our group for the reproducibility of 18 F-FDG PET images in a series of patients with squamous cell esophageal carcinoma (20). This study clearly demonstrated the lack of reproducibility by physicians of the delineation of hypoxic or proliferative tumoral volumes on PET/CT images.…”

Section: Discussionsupporting

confidence: 77%

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

et al. 2013

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

et al. 2013

Self Cite

View full text Add to dashboard Cite

“…One retrospective multi-center study demonstrated that the MTV defined by a physician significantly decreased from PET1 (pre-CRT) to PET2 (3 weeks from the start of CRT), whereas the MTV defined as 40% of the SUV max did not decrease significantly (25). The MTV from PET1 or PET2 was significantly lower in patients with CR at 3 months, while the SUV max was not.…”

Section: Discussionmentioning

confidence: 99%

18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy

Zhang¹,

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The aim of the present study was to explore the value of 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) in monitoring the early tumor response of esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CRT). A total of 48 patients with pathologically proven ESCC were retrospectively analyzed. All patients underwent two serial 18 F-FDG PET scans at baseline (pre-CRT) and 40 Gy/4 weeks of starting radiation therapy (inter-CRT). All patients received intensity-modulated radiotherapy (with a total radiation dose of 59.6 Gy) concurrently with cisplatin-based chemotherapy. The maximum standardized uptake value (SUV max ) and metabolic tumor volume (MTV) were measured using 18 F-FDG PET. The percentage changes (Δ) in SUV max and MTV between two serial scans were calculated and were revealed to be associated with the objective tumor response (oTR), according to the Response Evaluation Criteria in Solid Tumors 1.1. Among the 48 patients, 20.8% achieved a complete response, 68.8% exhibited a partial response and the oTR rate was 89.6%. On the pre-CRT PET scans, the mean SUV max and MTV were 14.1±5.8 and 58.2±25.4 cm . Univariate analysis revealed that ΔSUV max and ΔMTV were significantly associated with oTR (P= 0.010 and P= 0.001, respectively). ΔMTV was used as a predictor and a cut-off value of 54% discriminated responders from non-responders with a sensitivity of 69.8% and a specificity of 100% (P=0.001). The area under the receiver operating characteristic curve was 0.837 (95% confidence interval, 0.702-0.928). The results of the present study indicated that interim 18 F-FDG PET scans may provide early prognostic value for determining oTR in patients with ESCC undergoing treatment with CRT.

show abstract

“…However, to our knowledge, no ongoing trials have been launched using the TMTV to guide therapy. Even if the prerequisite for this type of trial is quality control, as done using various existing control systems (7,19,20), it is anyway required for good PET clinical practice. The main problem is which TMTV technique measurement should be chosen because there is no established consensus.…”

Section: Discussionmentioning

confidence: 99%

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to compare in a large series of peripheral T cell lymphoma, as a model of diffuse disease, the prognostic value of baseline total metabolic tumor volume (TMTV) measured on 18 F-FDG PET/CT with adaptive thresholding methods with TMTV measured with a fixed 41% SUV max threshold method. Methods: One hundred six patients with peripheral T cell lymphoma, staged with PET/CT, were enrolled from 5 Lymphoma Study Association centers. In this series, TMTV computed with the 41% SUV max threshold is a strong predictor of outcome. On a dedicated workstation, we measured the TMTV with 4 adaptive thresholding methods based on characteristic image parameters: Daisne (Da) modified, based on signal-to-background ratio; Nestle (Ns), based on tumor and background intensities; Fit, including a 3-dimensional geometric model based on spatial resolution (Fit); and Black (Bl), based on mean SUV max . The TMTV values obtained with each adaptive method were compared with those obtained with the 41% SUV max method. Their respective prognostic impacts on outcome prediction were compared using receiver-operatingcharacteristic (ROC) curve analysis and Kaplan-Meier survival curves. Results: The median value of TMTV 41% , TMTV Da , TMTV Ns , TMTV Fit , and TMTV Bl were, respectively, 231 cm 3 (range, 5-3,824), 175 cm 3 (range, 8-3,510), 198 cm 3 (range, 3-3,934), 175 cm 3 (range, 8-3,512), and 333 cm 3 (range, 3-5,113). The intraclass correlation coefficients were excellent, from 0.972 to 0.988, for TMTV Da , TMTV Fit , and TMTV Ns , and less good for TMTV Bl (0.856). The mean differences obtained from the Bland-Altman plots were 48.5, 47.2, 19.5, and 2253.3 cm 3 , respectively. Except for Black, there was no significant difference within the methods between the ROC curves (P . 0.4) for progression-free survival and overall survival. Survival curves with the ROC optimal cutoff for each method separated the same groups of low-risk (volume # cutoff) from high-risk patients (volume . cutoff), with similar 2-y progression-free survival (range, 66%-72% vs. 26%-29%; hazard ratio, 3.7-4.1) and 2-y overall survival (79%-83% vs. 50%-53%; hazard ratio, 3.0-3.5). Conclusion: The prognostic value of TMTV remained quite similar whatever the methods, adaptive or 41% SUV max , supporting its use as a strong prognosticator in lymphoma. However, for implementation of TMTV in clinical trials 1 single method easily applicable in a multicentric PET review must be selected and kept all along the trial. PET/ CT with 18 F-FDG has been recognized as the best imaging tool for staging and response assessment in FDG-avid lymphoma. The last International Conference on Malignant Lymphoma recommendations (1) encourage investigating the quantitative analysis of 18 F-FDG PET/CT at staging. In this regard, the measurement of the total metabolic tumor volume (TMTV), which gives an estimation of the total tumor burden, has gained special interest. Indeed, several series have shown that TMTV was predictive of outcome in different lymphoma subtypes: d...

show abstract

The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3)

Cited by 43 publications

References 39 publications

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Contact Info

Product

Resources

About

The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3)

Cited by 43 publications

References 39 publications

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3′-Deoxy-3′-18F-Fluorothymidine PET Images in Lung Cancer

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3′-Deoxy-3′-18F-Fluorothymidine PET Images in Lung Cancer

18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Contact Info

Product

Resources

About

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer